Leflunomid Pharmathen (Leflunomide)

Leflunomide is converted in the body to teriflunomide, an inhibitor of dihydroorotate dehydrogenase. By blocking this enzyme, the drug reduces pyrimidine synthesis, limiting the proliferation of activated T‑cells and other immune cells, thereby dampening the inflammatory response.

The dosing regimen for leflunomide is individualized and set by the prescribing clinician based on the patient’s condition, response, and tolerability. Typical initiation and maintenance doses are defined in the product’s prescribing information, but exact amounts should be confirmed by a qualified healthcare professional.

Leflunomide is classified as pregnancy category X, meaning it is contraindicated during pregnancy because of a high risk of fetal harm. It is also not recommended for breastfeeding mothers, as the drug can be excreted in breast milk and may affect the infant.

To order Leflunomid Pharmathen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Compared with conventional DMARDs such as methotrexate, leflunomide offers a once‑daily oral regimen and a distinct mechanism targeting pyrimidine synthesis. It may be chosen when patients cannot tolerate methotrexate or when disease activity remains uncontrolled. However, leflunomide carries specific liver‑related safety considerations that differ from other agents.

Leflunomid Pharmathen should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and excessive heat to maintain its stability and potency.

The medication is supplied as oral tablets that are swallowed whole with water. It can be taken with or without food, according to the prescriber’s instructions. Patients should follow the dosing schedule provided by their healthcare professional.

The most serious risks include severe liver injury, bone marrow suppression leading to anemia or leukopenia, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Additionally, leflunomide is teratogenic and must be avoided in pregnancy.

Leflunomide should not be used by pregnant women, individuals with pre‑existing severe liver disease, patients with active serious infections, or those with known hypersensitivity to the drug. Caution is also advised for patients with significant immunosuppression or uncontrolled hypertension.